# UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

#### FORM 8-K

## CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 30, 2012

#### **INSMED INCORPORATED**

(Exact Name of Registrant as Specified in Its Charter)

Virginia
(State or Other Jurisdiction of Incorporation)

0-30739 (Commission File Number)

54-1972729 (IRS Employer Identification No.)

9 Deer Park Drive, Monmouth Junction, New Jersey (Address of Principal Executive Offices)

08852 (Zip Code)

(732) 997-4600 (Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Edgar Filing: INSMED INC - Form 8-K

Item 8.01 Other Events.

On May 30, 2012, Insmed Incorporated (the "Company") issued a press release providing a corporate update, including the Company's current strategic development priorities for ARIKACE® (liposomal amikacin for inhalation).

A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Description

No.

99.1 Press release issued by Insmed Incorporated dated May 30, 2012.

## Edgar Filing: INSMED INC - Form 8-K

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Insmed Incorporated

Date: May 30, 2012

By: /s/ Kevin P. Tully C.G.A. Name: Kevin P. Tully C.G.A.

Title: Executive Vice President & Chief Financial Officer